Nimesulide PCD Pharma Franchise Company
Cafoli Lifecare is an established Nimesulide PCD pharma franchise company in India, offering 12 Nimesulide formulations across tablets and injection, including popular fixed-dose analgesic combinations. All products are manufactured at WHO-GMP certified, DCGI-approved facilities and offered to franchise partners with exclusive district-wise monopoly rights.
What is Nimesulide?
Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) of the sulfonanilide class, with relative selectivity for cyclo-oxygenase-2 (COX-2). By inhibiting COX-2 it reduces the synthesis of prostaglandins that mediate pain, inflammation and fever, giving it analgesic, anti-inflammatory and antipyretic activity. In India it is approved for the short-term management of acute pain and inflammatory conditions in adults, and it is contraindicated in children under 12 years. Compound data is available on PubChem.
Available Nimesulide Formulations
The Cafoli Lifecare Nimesulide range comprises 12 formulations in the following dosage forms:
Brand names, compositions, pack sizes and net rates are shared with registered franchise enquiries. Contact our team for the current Nimesulide price list.
Therapeutic Applications of Nimesulide
Prescribed for short-term use in adults, under medical supervision, for:
- Acute musculoskeletal and post-traumatic pain
- Post-operative and post-extraction dental pain
- Osteoarthritic pain flare-ups
- Primary dysmenorrhoea
- Painful inflammatory conditions of the ENT region
Prescriber specialties: orthopaedic surgeons, dentists, consulting physicians, gynaecologists and ENT specialists.
Safety note: Nimesulide is a prescription-only medicine intended for short-course use. It carries a recognised risk of hepatotoxicity and is contraindicated in children below 12 years of age in India. It must be promoted strictly within its approved indications and dispensed only against a valid prescription.
Why Nimesulide is a High-Potential Molecule for Distributors
Analgesics are the highest-volume therapeutic category in Indian retail pharma, and Nimesulide remains one of the most frequently written short-course NSAIDs in orthopaedic and dental practice. Its commercial strength for a franchise partner lies in breadth rather than depth: with 12 formulations spanning plain tablets, fixed-dose combinations and injection, a single molecule lets a distributor service orthopaedic clinics, dental chains, nursing homes and casualty departments from one line card. Acute-pain products also convert quickly — prescriptions are filled the same day, so stock turns fast and working capital is not tied up in slow-moving inventory the way it is with chronic-therapy SKUs.
Why Choose Cafoli Lifecare
- Monopoly rights — exclusive district-wise marketing rights for the Nimesulide range
- WHO-GMP certified manufacturing and DCGI-approved products
- Promotional inputs — visual aids, MR bags, prescription pads, samples and reminder cards
- 1000+ franchise partners across India with an on-time dispatch record
- Transparent net rates and dedicated franchise support
References
- PubChem — Nimesulide compound record
- PubMed — Nimesulide safety and hepatotoxicity literature
- CDSCO — Central Drugs Standard Control Organisation, India
Our formulations of Nimesulide find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: